Do analysts recommend SBTX or TLRY?

Tilray Brands has a consensus price target of $5.90, indicating a potential upside of 126.66%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tilray Brands 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.38

Do analysts rate SBTX or OCS?

Oculis has a consensus target price of $37.38, suggesting a potential upside of 376.24%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oculis 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

Do analysts prefer CTNM or SBTX?

Contineum Therapeutics presently has a consensus target price of $21.50, indicating a potential upside of 101.05%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CTNM or SBTX?

Contineum Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Contineum Therapeutics N/A N/A -$59.98M -$1.77 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is CTNM or SBTX more profitable?

Contineum Therapeutics' return on equity of -25.48% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -25.48% -24.28% Silverback Therapeutics N/A -29.62% -28.20%

Silverback Therapeutics (SBTX) Competitors

$3.57 +0.42 (+13.33%)

As of 11/10/2026

Compare

SBTX vs. TLRY, OCS, ASMB, CTNM, and FENC

Should you buy Silverback Therapeutics stock or one of its competitors? Silverback Therapeutics's main competitors and comparable companies include Tilray Brands (TLRY), Oculis (OCS), Assembly Biosciences (ASMB), Contineum Therapeutics (CTNM), and Adherex Technologies (FENC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silverback Therapeutics compare to Tilray Brands?

Silverback Therapeutics (NASDAQ:SBTX) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 1.6% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tilray Brands has a consensus price target of $5.90, indicating a potential upside of 126.66%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tilray Brands	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.38

Silverback Therapeutics has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Tilray Brands	$210.48M	1.83	-$121.40M	-$1.40	N/A

Silverback Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -16.91%. Tilray Brands' return on equity of -10.39% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Tilray Brands	-16.91%	-10.39%	-7.38%

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

In the previous week, Tilray Brands had 13 more articles in the media than Silverback Therapeutics. MarketBeat recorded 13 mentions for Tilray Brands and 0 mentions for Silverback Therapeutics. Tilray Brands' average media sentiment score of 0.66 beat Silverback Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Tilray Brands	Positive

Summary

Tilray Brands beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Silverback Therapeutics compare to Oculis?

Silverback Therapeutics (NASDAQ:SBTX) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Oculis has a consensus target price of $37.38, suggesting a potential upside of 376.24%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Oculis had 14 more articles in the media than Silverback Therapeutics. MarketBeat recorded 14 mentions for Oculis and 0 mentions for Silverback Therapeutics. Oculis' average media sentiment score of 0.08 beat Silverback Therapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Oculis	Neutral

Silverback Therapeutics has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Oculis	$1.45M	313.81	-$119.44M	-$1.71	N/A

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Oculis has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Silverback Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,613.92%. Silverback Therapeutics' return on equity of -29.62% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Oculis	-8,613.92%	-39.24%	-33.45%

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Oculis beats Silverback Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Silverback Therapeutics compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

In the previous week, Assembly Biosciences had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Assembly Biosciences and 0 mentions for Silverback Therapeutics. Assembly Biosciences' average media sentiment score of 0.01 beat Silverback Therapeutics' score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Silverback Therapeutics	Neutral

Assembly Biosciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Silverback Therapeutics has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Assembly Biosciences currently has a consensus price target of $46.50, indicating a potential upside of 117.70%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Assembly Biosciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Assembly Biosciences has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.02	-$6.12M	$1.02	20.94
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Assembly Biosciences beats Silverback Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Silverback Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

74.9% of Silverback Therapeutics shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Contineum Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Contineum Therapeutics had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for Contineum Therapeutics and 0 mentions for Silverback Therapeutics. Contineum Therapeutics' average media sentiment score of 0.45 beat Silverback Therapeutics' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Contineum Therapeutics	Neutral
Silverback Therapeutics	Neutral

Contineum Therapeutics' return on equity of -25.48% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-25.48%	-24.28%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Contineum Therapeutics presently has a consensus target price of $21.50, indicating a potential upside of 101.05%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Contineum Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.77	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Contineum Therapeutics beats Silverback Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Silverback Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Silverback Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Adherex Technologies currently has a consensus price target of $17.00, suggesting a potential upside of 58.97%. Given Adherex Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Adherex Technologies is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Adherex Technologies has higher revenue and earnings than Silverback Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$59.22M	6.36	-$9.74M	-$0.13	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Adherex Technologies has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

In the previous week, Adherex Technologies had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Adherex Technologies and 0 mentions for Silverback Therapeutics. Adherex Technologies' average media sentiment score of 0.46 beat Silverback Therapeutics' score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Neutral
Silverback Therapeutics	Neutral

Summary

Adherex Technologies beats Silverback Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$128.73M	$13.79B	$7.89B	$12.22B
Dividend Yield	N/A	2.58%	2.47%	4.44%
P/E Ratio	-1.48	30.26	35.35	30.86
Price / Sales	N/A	6.93	8.40	5.81
Price / Cash	N/A	15.75	22.22	22.66
Price / Book	0.48	5.00	4.43	3.79
Net Income	-$89.48M	$2.86B	$3.50B	$390.16M
7 Day Performance	17.05%	0.03%	-0.97%	-1.10%
1 Month Performance	-15.60%	-5.38%	-4.07%	-6.19%
1 Year Performance	-59.80%	-5.73%	2.04%	-5.75%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$3.57 +13.3%	N/A	-64.4%	$128.73M	N/A	N/A	83	High Trading Volume
TLRY Tilray Brands	3.6867 of 5 stars	$2.81 -5.1%	$5.90 +110.0%	-79.8%	$437.45M	$915.45M	N/A	3,595
OCS Oculis	2.8148 of 5 stars	$6.83 -6.2%	$38.89 +469.4%	-60.9%	$422.13M	$1.45M	N/A	60
ASMB Assembly Biosciences	2.8346 of 5 stars	$20.00 +0.7%	$46.50 +132.5%	-33.4%	$404.57M	$72.30M	19.48	73	Analyst Downgrade Gap Up High Trading Volume
CTNM Contineum Therapeutics	2.0123 of 5 stars	$8.81 -10.0%	$21.50 +144.0%	-2.7%	$368.31M	$50M	N/A	51	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. TLRY, OCS, ASMB, CTNM, and FENC

How does Silverback Therapeutics compare to Tilray Brands?

Summary

How does Silverback Therapeutics compare to Oculis?

Summary

How does Silverback Therapeutics compare to Assembly Biosciences?

Summary

How does Silverback Therapeutics compare to Contineum Therapeutics?

Summary

How does Silverback Therapeutics compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. TLRY, OCS, ASMB, CTNM, and FENC

How does Silverback Therapeutics compare to Tilray Brands?

Do institutionals & insiders believe in SBTX or TLRY?

Do analysts recommend SBTX or TLRY?

Which has stronger earnings and valuation, SBTX or TLRY?

Is SBTX or TLRY more profitable?

Which has more volatility & risk, SBTX or TLRY?

Does the media prefer SBTX or TLRY?

Summary

How does Silverback Therapeutics compare to Oculis?

Do analysts rate SBTX or OCS?

Does the media prefer SBTX or OCS?

Which has better earnings & valuation, SBTX or OCS?

Which has more risk and volatility, SBTX or OCS?

Is SBTX or OCS more profitable?

Do insiders and institutionals have more ownership in SBTX or OCS?

Summary

How does Silverback Therapeutics compare to Assembly Biosciences?

Does the media favor ASMB or SBTX?

Which has more volatility & risk, ASMB or SBTX?

Is ASMB or SBTX more profitable?

Do analysts prefer ASMB or SBTX?

Which has preferable valuation & earnings, ASMB or SBTX?

Do insiders and institutionals hold more shares of ASMB or SBTX?

Summary

How does Silverback Therapeutics compare to Contineum Therapeutics?

Do institutionals & insiders believe in CTNM or SBTX?

Which has more volatility and risk, CTNM or SBTX?

Does the media prefer CTNM or SBTX?

Is CTNM or SBTX more profitable?

Do analysts prefer CTNM or SBTX?

Which has preferable valuation and earnings, CTNM or SBTX?

Summary

How does Silverback Therapeutics compare to Adherex Technologies?

Do insiders and institutionals hold more shares of FENC or SBTX?

Is FENC or SBTX more profitable?

Do analysts rate FENC or SBTX?

Which has better valuation & earnings, FENC or SBTX?

Which has more risk and volatility, FENC or SBTX?

Does the media favor FENC or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools